------ =_NextPart_000_01BBE611.B38E4AA0
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable
It was fascinating to read Brian Collins' note about carbidopa, and the =
postulated activity of the excess carbidopa being let loose contributing =
to fatigue, etc.
In our household we have the "other" levadopa source - not Sinemet, but =
Madopar. Instead of including carbidopa, it has as a partner another =
substance called Benserazide. In our tablets the proportion is half that =
of the l-dopa.
Might it be expected that the same effect could result from excess =
benserazide as from excess carbidopa? And if so, at what threshold level =
would an effect be suspected?
Is there a Madopar product that contains a proportionally lower ratio of =
benserazide to l-dopa?
Robyn & John Lochore
Perth, Western Australia
------ =_NextPart_000_01BBE611.B38E4AA0
Content-Type: application/ms-tnef
Content-Transfer-Encoding: base64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------ =_NextPart_000_01BBE611.B38E4AA0--
